Vega Nutritionals Ltd - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

invega trinza paliperidone (as palmitate) 263 mg modified release suspension for injection pre-filled syringe

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

invega trinza paliperidone (as palmitate) 175 mg modified release suspension for injection pre-filled syringe

Australia - English - Department of Health (Therapeutic Goods Administration)

invega paliperidone 12mg modified release tablet blister pack

janssen-cilag pty ltd - paliperidone, quantity: 12 mg - tablet, modified release - excipient ingredients: polyethylene oxide; sodium chloride; povidone; stearic acid; butylated hydroxytoluene; iron oxide yellow; iron oxide red; hyetellose; macrogol 3350; cellulose acetate; hypromellose; titanium dioxide; macrogol 400; carnauba wax; iron oxide black; purified water; isopropyl alcohol; propylene glycol - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

United States - English - NLM (National Library of Medicine)

invega- paliperidone tablet, extended release

tya pharmaceuticals - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - invega (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia . ® [see ] clinical studies (14.1) the efficacy of invega in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. ® invega (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy . ® [see ] clinical studies (14.2) the efficacy of invega in schizoaffective disorder was established in two 6-week trials in adults. ® hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega (paliperidone) i